All | Survival | Mortality | p | Telbivudine | Entecavir | p | |
---|---|---|---|---|---|---|---|
Patient no | 21 | 17 | 4 | 9 | 12 | ||
Age | 48 (28–71) | 49 (28–71) | 36.5 (29–51) | 0.226 | 48 (29–65) | 47 (28–71) | 0.859 |
Gender | 1.000 | 1.000 | |||||
Male | 18 | 14 | 4 | 8 | 10 | ||
Female | 3 | 3 | 0 | 1 | 2 | ||
LdT/ETV | 9/12 | 7/10 | 2/2 | 1.000 | − | − | − |
Mortality | − | − | − | − | 2 | 2 | 1.000 |
HBeAg+ | 9 | 7 | 2 | 1.000 | 3 | 6 | 0.660 |
Cirrhosis | 3 | 2 | 1 | 0.489 | 1 | 2 | 1.000 |
Ascites | 3 | 1 | 2 | 0.080 | 1 | 2 | 1.000 |
Encephalopathy | 1 | 1 | 0 | 0.190 | 1 | 0 | 0.429 |
FU (M) | 19.4 (0.8–28.2) | 25.0 (4.0–28.2) | 1.45 (0.8–2.5) | 0.002 | 5.1 (1.9–28.2) | 24.7 (0.8–27.7) | 0.722 |
Albumin | 3.49 (2.5–4.9) | 3.6 (2.5–4.9) | 2.95 (2.5–3.3) | 0.020 | 3.6 (2.9–4.2) | 3.4 (2.5–4.9) | 0.477 |
ALT | 1270 (146–2480) | 1270 (211–2480) | 1197 (146–2247) | 0.929 | 1523 (211–2480) | 870 (146–2247) | 0.177 |
Bilirubin T | 9.2 (2.1–33.1) | 7.7 (2.1–16.8) | 20.6 (11.9–33.1) | 0.007 | 8.6 (2.1–20.4) | 10.25 (2.2–33.1) | 0.356 |
Creatinine | 0.68 (0.39–1.46) | 0.71 (0.47–1.34) | 0.48 (0.39–1.46) | 0.165 | 0.71 (0.47–1.05) | 0.63 (0.39–1.46) | 0.972 |
eGFR | |||||||
MDRD | 116 (53–254) | 116 (53–183) | 194.5 (54–254) | 0.106 | 116 (73–201) | 127 (53–254) | 0.831 |
CKD-EPI | 111.1 (52.9–156.7) | 110.1 (52.9–131.1) | 138.2 (59.8–156.7) | 0.152 | 112 (77.8–148) | 110.6 (52.9–156.7) | 0.722 |
Platelet (103) | 148 (44–253) | 148 (62–253) | 121.5 (44–174) | 0.244 | 174 (44–251) | 121.5 (62–253) | 0.188 |
INR | 1.6 (1.3–3.5) | 1.5 (1.3–2.3) | 3.3 (2.6–3.5) | 0.002 | 1.5 (1.3–3.1) | 1.6 (1.4–3.5) | 0.773 |
AFP | 65.7 (4.1–650.7) | 49.4 (4.1–477.2) | 109.5 (27.9–650.7) | 0.325 | 27.9 (4.2–238.3) | 162.1 (4.1–650.7) | 0.088 |
HBV DNA (log10 cps/ml) | 8.04 (4.3–9.68) | 8.16 (5.22–9.68) | 5.06 (4.30–8.20) | 0.031 | 8.04 (4.97–9.47) | 8.04 (4.30–9.68) | 0.886 |
MELD score | 20 (13–37) | 19 (13–28) | 31.5 (26–37) | 0.003 | 19 (14–31) | 20 (13–37) | 0.412 |